LOX Fails to Substitute for RANKL in Osteoclastogenesis

Journal of Bone and Mineral Research

Volumn 32, Issue 3, 2017, Pages 434-439

  Tsukasaki, Masayuki ^a   Hamada, Koki ^a   Okamoto, Kazuo ^a   Nagashima, Kazuki ^a   Terashima, Asuka ^a   Komatsu, Noriko ^a   Win, Stephanie J ^a   Okamura, Tadashi ^b   Nitta, Takeshi ^a   Yasuda, Hisataka ^c   Penninger, Josef M ^d   Takayanagi, Hiroshi ^a  

^a UNIVERSITY OF TOKYO   (Japan)

^b NATIONAL CENTER FOR GLOBAL HEALTH AND MEDICINE   (Japan)

^c Oriental Yeast Co Ltd   (Japan)

^d INSTITUTE OF MOLECULAR BIOTECHNOLOGY   (Austria)

Author keywords

OSTEOCLAST; OSTEOIMMUNOLOGY; RANKL

Indexed keywords

ACID PHOSPHATASE TARTRATE RESISTANT ISOENZYME; COLONY STIMULATING FACTOR 1; HYDROGEN PEROXIDE; OSTEOCLAST DIFFERENTIATION FACTOR; PROTEIN LYSINE 6 OXIDASE; REACTIVE OXYGEN METABOLITE; TRANSCRIPTION FACTOR NFAT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BONE MARROW STROMA CELL; CELL CULTURE; CELL PROLIFERATION; CONTROLLED STUDY; DENTIN SLICE; ENZYME ACTIVITY; HUMAN; HUMAN CELL; IN VIVO STUDY; MESENCHYMAL STROMA CELL; MONOCYTE MACROPHAGE PRECURSOR CELL; MOUSE; MULTINUCLEAR CELL; NONHUMAN; OSTEOCLAST; OSTEOCLASTOGENESIS; OSTEOLYSIS; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; ANIMAL; BONE DEVELOPMENT; C57BL MOUSE; DRUG EFFECTS; METABOLISM;

ANIMALS; CELLS, CULTURED; HUMANS; MICE, INBRED C57BL; OSTEOCLASTS; OSTEOGENESIS; PROTEIN-LYSINE 6-OXIDASE; RANK LIGAND;

EID: 84990842063     PISSN: 08840431     EISSN: 15234681     Source Type: Journal    
DOI: 10.1002/jbmr.2990     Document Type: Article

References (20)

1. Kong YY, Yoshida H, Sarosi I, et al. OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature. 1999; 397:315–23.
2. Takayanagi H. Osteoimmunology: shared mechanisms and crosstalk between the immune and bone systems. Nat Rev Immunol. 2007; 7:292–304.
3. Hemingway F, Kashima TG, Knowles HJ, Athanasou NA. Investigation of osteoclastogenic signalling of the RANKL substitute LIGHT. Exp Mol Pathol. 2013; 94:380–5.
4. Hemingway F, Taylor R, Knowles HJ, Athanasou NA. RANKL-independent human osteoclast formation with APRIL, BAFF, NGF, IGF I and IGF II. Bone. 2011; 48:938–44.
5. Kim JH, Jin HM, Kim K, et al. The mechanism of osteoclast differentiation induced by IL-1. J Immunol. 2009; 183:1862–70.
6. Kobayashi K, Takahashi N, Jimi E, et al. Tumor necrosis factor-α stimulates osteoclast differentiation by a mechanism independent of the ODF/RANKL-RANK interaction. J Exp Med. 2000; 191:275–85.
7. Lam J, Takeshita S, Barker JE, Kanagawa O, Ross FP, Teitelbaum SL. TNF-α induces osteoclastogenesis by direct stimulation of macrophages exposed to permissive levels of RANK ligand. J Clin Invest. 2000; 106:1481–8.
8. Kim N, Kadono Y, Takami M, et al. Osteoclast differentiation independent of the TRANCE-RANK-TRAF6 axis. J Exp Med. 2005; 202:589–95.
9. Li J, Sarosi I, Yan XQ, et al. RANK is the intrinsic hematopoietic cell surface receptor that controls osteoclastogenesis and regulation of bone mass and calcium metabolism. Proc Natl Acad Sci U S.A. 2000; 97:1566–71.
10. Cox TR, Rumney RM, Schoof EM, et al. The hypoxic cancer secretome induces pre-metastatic bone lesions through lysyl oxidase. Nature. 2015; 522:106–10.
11. Nakashima T, Hayashi M, Takayanagi H. New insights into osteoclastogenic signaling mechanisms. Trends Endocrinol Metab. 2012; 11:582–90.
12. Kitaura H, Sands MS, Aya K, et al. Marrow stromal cells and osteoclast precursors differentially contribute to TNF-α-induced osteoclastogenesis in vivo. J. Immunol. 2004; 173:4838–46.
13. Hanada R, Leibbrandt A, Hanada T, et al. Central control of fever and female body temperature by RANKL/RANK. Nature. 2009; 462:505–9.
14. Guerrini MM, Okamoto K, Komatsu N, et al. Inhibition of the TNF family cytokine RANKL prevents autoimmune inflammation in the central nervous system. Immunity. 2015; 43:1174–85.
15. Takayanagi H, Kim S, Koga T, et al. Induction and activation of the transcription factor NFATc1 (NFAT2) integrate RANKL signaling in terminal differentiation of osteoclasts. Dev Cell. 2002; 3:889–901.
16. Yamamoto Y, Udagawa N, Matsuura S, et al. Osteoblasts provide a suitable microenvironment for the action of receptor activator of nuclear factor-κB ligand. Endocrinology. 2006; 147:3366–74.
17. Pilz GA, Braun J, Ulrich C, et al. Human mesenchymal stromal cells express CD14 cross-reactive epitopes. Cytometry A. 2011; 79:635–45.
18. Bai XC, Lu D, Liu AL, et al. Reactive oxygen species stimulates receptor activator of NF-κB ligand expression in osteoblast. J Biol Chem. 2005; 280:17497–506.
19. Zhang Y, Zhang Y, Kou J, Wang C, Wang K. Role of reactive oxygen species in angiotensin II: induced receptor activator of nuclear factor-κB ligand expression in mouse osteoblastic cells. Mol Cell Biochem. 2014; 396:249–55.
20. Knoop KA, Kumar N, Butler BR, et al. RANKL is necessary and sufficient to initiate development of antigen-sampling M cells in the intestinal epithelium. J Immunol. 2009; 183:5738–47.